-
Company Insights
Innovation and Patenting activity of CD Projekt RED SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CD Projekt RED SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CD-388 in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Seasonal Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Seasonal Influenza Drug Details:CD-388 is under development for the treatment and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CD-388 in Pandemic Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Pandemic Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Pandemic InfluenzaDrug Details:CD-388 is under development for the treatment and prevention...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CD-388 in Influenzavirus B Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Influenzavirus B Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Influenzavirus B Infections Drug Details:CD-388 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furestem-CD in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Furestem-CD in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Furestem-CD in Crohn's Disease (Regional Enteritis) Drug Details: Furestem-CD...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Soft Tissue Sarcoma Drug Details: Regorafenib (BAY 73-4506,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LuAG-13909 in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LuAG-13909 in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Drug Details: LuAG-13909 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-001 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-001 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-001 in Non-Hodgkin Lymphoma Drug Details: AVA-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-001 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-001 in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-001 in Non-Hodgkin Lymphoma Drug Details: AVA-001 is under development for the...